Chad A. Mirkin,Caroline H. Ko,David A. Giljohann,Janina Luciano,Samuel A. Jensen,Alexander Stegh
申请号：
US15858142
公开号：
US20180193484A1
申请日:
2017.12.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
